TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Age. 12-80 Documented physician-diagnosed asthma for at least 12 months Subjects who have received a physician-prescribed asthma controller medication with medium or high dose ICS for at least 12 months.~Documented treatment with a total daily dose of either medium or high dose ICS (≥ 500 µg fluticasone propionate dry powder formulation equivalent total daily dose) for at least 3 months.~At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months.~Documented history of at least 1 asthma exacerbation events within 12 months. ACQ-6 score ≥1.5 at screening or on day of registration.~Exclusion Criteria:~Pulmonary disease other than asthma. History of cancer. History of a clinically significant infection. Current smokers or subjects with smoking history ≥10 pack-yrs. History of chronic alcohol or drug abuse within 12 months. Hepatitis B, C or HIV. Pregnant or breastfeeding. History of anaphylaxis following any biologic therapy. Subject randomized in the current study or previous tezepelumab studies

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tezepelumab (Type: EXPERIMENTAL): Tezepelumab: Tezepelumab subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Calcium and Bone Mass in Young Females

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pubertal stage II~* Calcium intake below a threshold level~* Caucasian~* Normal health~Exclusion Criteria:~* Medications affecting calcium and bone metabolism~* Chronic diseases~* Metabolic bone disease~* Abnormality in calcium metabolism

- Gender: FEMALE
- Minimum Age: 8 Years
- Maximum Age: 13 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of acute myeloid leukemia (AML), either M4 or M5 subtype de novo or resulting from a transformation from MDS or a myeloproliferative disorder.~* Patients with AML who (a) have failed primary therapy -defined as failing two induction chemotherapies, (b) have relapsed or (c) are not suitable for intensive induction chemotherapy will be eligible. OR~* Patients with AML blast crisis from CML if they are not suitable candidates for intensive induction chemotherapy or have failed imatinib mesylate OR~* Patients with secondary AML after MDS if they are not suitable candidates for intensive induction chemotherapy.~* ECOG 0,1,2, or 3~* Life expectancy \> 12 weeks.~* Adequate renal and hepatic function~Exclusion Criteria:~* Uncontrolled central nervous system involvement by AML~* Active cardiovascular disease as defined by NYHA class III-IV categorization.~* Intercurrent illness or medical condition precluding safe administration of ribavirin.~* Received any previous therapy within 28 days prior to study entry.Hydrea is permitted but must be stopped 7 days prior to starting study drug.~* Known infection with HIV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): Ribavirin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with previously treated, therapy-refractory or -intolerant, Stage III (unresectable) or Stage IV melanoma

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tailored Hydration for the Prevention of Post-ERCP Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients older than 20 years undergoing ERCP for the 1st time will be recruited~Exclusion Criteria:~* Age below 20 or above 80 years~* Underlying severe psychiatric illness~* Cardiac insufficiency (\>New York Heart Association Class II heart failure)~* Renal insufficiency (eGFR \<30mililiter/min/1.73m2)~* Respiratory insufficiency (defined as oxygen saturation \< 90%)~* Poorly controlled blood sugar~* Ongoing hypotension including those with sepsis~* Ongoing acute pancreatitis~* Underlying disease of chronic pancreatitis~* Clinical signs of hypervolemia~* Hyponatremia (Na+ levels \< 130 milliequivalent (mEq)/L))~* Hypernatremia (Na+ levels \> 150mEq/L)~* Hyperkalemia (5.1 mEq/dL)~* Metabolic alkalosis~* Past history of endoscopic sphincterectomy or endoscopic papillary balloon dilatation

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tailored standard hydration (Type: ACTIVE_COMPARATOR): Patients will be randomly allocated to tailored standard hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 1.5 milliliter(mL)/kg/hr during and after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
- Tailored aggressive hydration (Type: EXPERIMENTAL): Patients will be randomly allocated to tailored aggressive hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg over 1 hour after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine in the Treatment of Suicidal Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Unipolar depression with current major depressive episode (MDE). Participants may be psychiatric medication-free, or if on psychiatric medication, not responding adequately given current MDE with suicidal ideation (See 2).~* Moderate to severe suicidal ideation~* 18-65 years old~* Participants must agree to a voluntary admission to an inpatient research unit at the New York State Psychiatric Institute (NYSPI)for the infusion(s), for a brief stay, or longer if clinically necessary.~* Pre-menopausal female participants of child-bearing potential must be willing to use an acceptable form of birth control during study participation such as condoms, diaphragm, or oral contraceptive pills.~* Able to provide informed consent~* Participants 61-65 years old must score a 25 or higher on the Mini-Mental State Examination (MMSE) at screening.~EXCLUSION CRITERIA:~* Unstable medical condition or neurological illness, including baseline hypertension (BP\>140/90) or significant history of cardiovascular illness.~* Significant ECG abnormality~* Pregnant or lactating~* Diagnosis of bipolar disorder or psychotic disorder~* Contraindication to any study treatment.~* Inadequate understanding of English.~* Prior ineffective trial of or adverse reaction to Ketamine or Midazolam.~* Opiate use greater than total daily dose of 20mg Oxycodone or equivalent during the 3 days pre-infusion.~* A diagnosis of sleep apnea.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Midazolam (Type: ACTIVE_COMPARATOR): 0.02 mg/kg, I.V. (in the vein)
- Ketamine (Type: ACTIVE_COMPARATOR): 0.5 mg/kg, I.V. (in the vein)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent obtained.~2. Subject randomized within 24 hr of completion of transplant surgery.~3. Recipient of a kidney with a cold ischemia time \< 30 hours.~4. Recipient of a primary (or secondary, if first graft is not lost due to immunological reasons) renal transplant from a deceased heart beating, living unrelated, living related non-human leukocyte antigen identical or an expanded criteria donor.~Exclusion Criteria:~1. Subject unable to tolerate oral medication at time of randomization.~2. Use of other investigational drugs at the time of enrollment.~3. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.~4. Multi-organ transplant recipient.~5. Recipient of ABO incompatible allograft or complement-dependent lymphocytotoxic (CDC) crossmatch positive transplant.~6. Subject at high immunological risk for rejection as determined by local practice for assessment of anti-donor reactivity e.g. high PRA, presence of pre-existing DSA.~7. Subject who is HIV-positive.~8. HBsAg and/or a HCV positive subject with evidence of elevated LFTs (ALT/AST levels ≥ 2.5 times ULN). Viral serology results obtained within 6 months prior to randomization are acceptable.~9. Recipient of a kidney from a donor who tests positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV).~10. Subject with a BMI greater than 35.~11. Subject with severe systemic infections, current or within the two weeks prior to randomization.~12. Subject requiring systemic anticoagulation.~13. History of malignancy of any organ system.~14. Subject with severe restrictive or obstructive pulmonary disorders.~15. Subject with severe hypercholesterolemia or hypertriglyceridemia that cannot be controlled.~16. Subject with white blood cell (WBC) count ≤ 2,000 /mm3 or with platelet count ≤ 50,000 /mm3.~17. Pregnant or nursing (lactating) women.~18. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EVR+rCNI (Type: EXPERIMENTAL): Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
- MPA+sCNI (Type: ACTIVE_COMPARATOR): Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lower Third Molar Removal With 2% and 4% Articaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Need of lower third molar surgeries in similar positions~Exclusion Criteria:~* Presence of systemic diseases;~* Presence of local inflammation and/or infection;~* Any history of allergic reaction to local anesthetics, gastrointestinal bleeding or ulceration;~* Cardiovascular and kidney diseases;~* Asthma and allergy to aspirin, piroxicam or any other non-steroidal antiinflammatory drug;~* Regular use of any non-steroidal antiinflammatory drug, pregnancy or breast feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Surgery With 2% Articaine first, then Surgery With 4%Articaine (Type: EXPERIMENTAL): First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
- Surgery With 4%Articaine first, then Surgery With 2% Articaine (Type: EXPERIMENTAL): First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 - 70 years old at registration~* Type 1 or Type 2 diabetes mellitus for at least 2 years~* Symptoms of gastroparesis (nausea, vomiting, early satiety, bloating, fullness, discomfort) for at least 1 year prior to registration~* Gastroparesis Cardinal Symptom Index (GCSI) score of 18~* Delayed gastric emptying on gastric scintigraphy within 1 year of registration, defined as greater than 60% retention at 2 hours or greater than 10% retention at 4 hours~* Hemoglobin A1c of at least 8.0% at registration regardless of current therapy. Individuals already receiving diabetes therapy via an insulin pump will be eligible for study participation if, in the opinion of the investigators, he/she may acquire additional benefit from continuous glucose monitoring that might improve glycemic control~* Normal upper endoscopy within 1 year of registration~* No clinical or imaging evidence of obstruction~* Successful mastering of use of CGMS during the run-in period~Exclusion Criteria:~* Prior gastric surgery including fundoplication~* Other systemic disease potentially causative of gastrointestinal symptoms~* Acute or chronic renal insufficiency with creatinine \>1.5 mg/dL~* Psychiatric disease or eating disorder~* Pregnancy~* Any other condition which, in the opinion of the investigators, would impede compliance or hinder completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CGMS and insulin pump (Type: EXPERIMENTAL): Continuous glucose monitoring in conjunction with insulin pump

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will be eligible if they were randomized to study A3051123.~Exclusion Criteria:~* Participation in study A3051123 ceased (ie, withdrew consent, lost to follow-up, etc) prior to final visit of study A3051123.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- placebo (Type: EXPERIMENTAL): None
- varenicline (Type: EXPERIMENTAL): None
- bupropion (Type: EXPERIMENTAL): None
- Nicotine Replacement Therapy Patch (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drotaverine to Shorten the Length of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged between 18 and less than 35 years.~* Primigravidae.~* Singleton pregnancy.~* Term gestation i.e., 37-42 weeks.~* Sure, reliable dates documented by ultrasound in the 1st half of pregnancy.~* Vertex presentation with occipito anterior position~* Regular uterine contractions at a rate of at least 3 to 4 contractions every 10 minutes, each contraction lasting for at least 40 seconds.~* Cervical dilatation of 3-5 cm.~* With or without rupture of membranes~* No evidence of maternal or fetal distress.~Exclusion Criteria:~* Cephalo-pelvic disproportion.~* Cervical surgery in the past or history of cervical injury.~* Patients on antihypertensive therapy.~* Known hypersensitivity to Drotaverine hydrochloride.~* If any other spasmolytic agent had been used within 48 hours.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Drotaverine (Type: ACTIVE_COMPARATOR): Women who will receive 40 mg Drotaverine hydrochloride (Do-Spa) IV injection.
- Placebo (Type: PLACEBO_COMPARATOR): Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Open Label Continuation Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Participant was in a prior D2E7 (adalimumab) study~* Participant was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.~Exclusion Criteria~* Participant was considered by the investigator, for any reason, to be an unsuitable candidate for the study~* Participant was a female subject who is pregnant or breast-feeding or considering becoming pregnant~* Participant had any ongoing chronic or active infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: EXPERIMENTAL): Open-label adalimumab 40 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>18 years old~* Negative urine culture within 1 month prior to procedure~* Renal Calculi which would optimally require PCNL for treatment.~Exclusion Criteria:~* Patients \<18 years old.~* Patients who are not able to give consent for study~* Patients currently on antibiotics immediately prior to the procedure~* Previous history of sepsis or SIRS from stone manipulations~* Foley catheter in place for greater than 1 week duration~* Patients under going planned, multi-staged procedures~* Immunosuppressed patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Antibiotics for a 24 hour period (Type: ACTIVE_COMPARATOR): Antibiotics for a 24 hour period~Intervention drug to be determined based on patient history etc.
- Continued antibiotics (Type: ACTIVE_COMPARATOR): Continued antibiotics until the removal of any external catheters~Intervention drug to be determined based on patient history etc.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endothelial Dysfunction in Obese Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Children with severe obesity~* Younger than 16 yrs: BMI ≥97th sex and age specific BMI-percentile~* Older than 16 yrs: BMI ≥35 kg/m²~Exclusion Criteria:~* Acute or chronic inflammatory process, use of non-steroidal anti- inflammatory drugs or immunosuppressive drugs. (including inhalation corticosteroids).~* Structural heart disease or other cardiac diseases.~* Active malignant hematological disease

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Exercise training (Type: EXPERIMENTAL): Individualized and progressively increased supervised aerobic exercise program on a daily base (3-4hours per day, hypocaloric diet and psychological guidance
- Usual Care (Type: OTHER): Nutritional assessment and dietary advice by general practitioner, promotion of sports activities

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete